Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ONCTERNAL THERAPEUTICS, INC.

(ONCT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
3.79(c) 3.84(c) 3.81(c) 3.72(c) 3.68(c) Last
335 178 334 778 346 190 344 688 479 425 Volume
-2.07% +1.32% -0.78% -2.36% -1.08% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 3,37 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Sales 2022 3,28 M - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 182 M 182 M -
Capi. / Sales 2021 54,0x
Capi. / Sales 2022 55,4x
Nbr of Employees 13
Free-Float 88,2%
More Financials
Company
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of cancers with critical unmet medical need. The CompanyÔÇÖs clinical pipeline includes cirmtuzumab, TK216, ROR1 CAR-T. Cirmtuzumab is a monoclonal antibody that is designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) for the treatment of... 
More about the company
All news about ONCTERNAL THERAPEUTICS, INC.
10/08ONCTERNAL THERAPEUTICS : AACR-NCI-EORTC Molecular Targets and Cancer Therapuetics Conferen..
PU
10/05ONCTERNAL THERAPEUTICS' : Potential Prostate Cancer Drug Shows Anti-Tumor Activity in Prec..
MT
10/05ONCTERNAL THERAPEUTICS : Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N..
AQ
10/05Oncternal Therapeutics, Inc. Announces Pre-Clinical Data from ONCT-534, an Androgen Rec..
CI
10/01ONCTERNAL THERAPEUTICS : Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5..
AQ
09/20ONCTERNAL THERAPEUTICS : Celularity Collaborating on Targeted Placental-Derived Cellular T..
MT
09/20Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Tar..
GL
09/20CELULARITY : and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targ..
AQ
09/20Celularity Inc. and Oncternal Therapeutics, Inc. Enter into Research Collaboration to E..
CI
09/20ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to S&P Global BMI Index
CI
09/09ONCTERNAL THERAPEUTICS : to Participate in September Investor Conferences
AQ
09/01ONCTERNAL THERAPEUTICS : Rounds Out Leadership Team with Appointment of Steven Hamburger, ..
AQ
08/05ONCTERNAL THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
08/05Oncternal Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June..
CI
08/05ONCTERNAL THERAPEUTICS : Q2 Earnings Snapshot
AQ
More news
News in other languages on ONCTERNAL THERAPEUTICS, INC.
10/05Le médicament potentiel d'Oncternal Therapeutics contre le cancer de la prostate montre..
09/20Oncternal et Celularity collaborent dans le domaine des thérapies cellulaires ciblées d..
More news
Analyst Recommendations on ONCTERNAL THERAPEUTICS, INC.
More recommendations
Chart ONCTERNAL THERAPEUTICS, INC.
Duration : Period :
Oncternal Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCTERNAL THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,68 $
Average target price 15,50 $
Spread / Average Target 321%
Managers and Directors
James B. Breitmeyer President, Chief Executive Officer & Director
Richard Glenn Vincent Chief Financial Officer, Secretary & Treasurer
David F. Hale Chairman
Rajesh Krishnan Chief Technology Officer
Gunnar F. Kaufmann Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCTERNAL THERAPEUTICS, INC.-24.90%182
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455